In this study we reported the synthesis of biocompatible Hydroxyapatite (HAP)/Silk Fibroin (SF)/Chitosan (CT) composite by using In-situ co-precipitation method. Trace of carbonated hydroxyapatite with low crystallinity serves as a promising platform for the growth of bone tissue and were confirmed using Fourier Transfer Infrared (FTIR) spectroscopy, which is in accordance with X-Ray Diffraction (XRD) results. In-vitro bioactivity of the composite was analysed by treating it with Simulated Body Fluid (SBF) solution for two consecutive weeks. A maximum degradation rate of 30.28 ± 0.57% was observed for the first week and 23.89 ± 0.58% for the latter week, which confirms the increase in mineralization of the composite. The cytotoxicity of the composite was assessed using MTT-assay countered to MG-63 osteoblast like cell line, which reveals that all the composites are less toxic. Dependence of the antibacterial effect of composite on the type of bacteria were examined which reflects the better antibacterial activity of the composite to Gram-negative than Gram-positive. The potential of the 40% HAP- 30% SF- 30% CT composite (HSC-3) as a promising candidate for bone tissue engineering could be further confirmed from the future in-vivo studies for which the findings in the present study remains supportive.

在这项研究中，我们报告了使用原位共沉淀法合成生物相容性羟基磷灰石（HAP）/丝素蛋白（SF）/壳聚糖（CT）的复合材料。低结晶度的碳酸羟基磷灰石的痕迹为骨组织的生长提供了有希望的平台，并已通过傅立叶转移红外（FTIR）光谱进行了证实，这与X射线衍射（XRD）结果一致。体外通过用模拟体液（SBF）溶液处理连续两周来分析复合材料的生物活性。在第一周观察到最大降解速率为30.28±0.57％，在第二周观察到最大降解速率为23.89±0.58％，这证实了复合材料矿化的增加。使用针对MG-63成骨细胞样细胞系的MTT分析评估了复合材料的细胞毒性，这表明所有复合材料的毒性都较小。检查了复合材料的抗菌效果对细菌类型的依赖性，这反映了复合材料对革兰氏阴性菌的抗菌活性要好于革兰氏阳性菌。40％HAP-30％SF-30％CT复合材料（HSC-3）作为骨组织工程的有希望的候选者的潜力可以从未来的体内进一步证实 本研究中的发现仍然支持的研究。